An Open Label Phase II Trial to Assess the Efficacy and Safety of a Once Daily Oral Dose of 50 mg BIBW 2992 in Two Cohorts of Patients With HER2-Negative Metastatic Breast Cancer After Failure of no More Than Two Chemotherapy Regimen.
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2013
At a glance
- Drugs Afatinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 12 Jul 2011 New source identified and integrated (European Clinical Trials Database).
- 12 Jul 2011 EudraCT reports actual initiation date 31 Oct 2006, actual end date is 31 Jan 2009, trial status is discontinued.
- 02 Jun 2009 Planned number of patients changed from 60 to 50 as reported by ClinicalTrials.gov.